Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | NR2F1-AS1 | Human | 17beta-estradiol | affects response to substance | EXP | | 6480464 | NR2F1-AS1 gene SNP affects the susceptibility to Estradiol | CTD | PMID:25622337 | NR2F1-AS1 | Human | antirheumatic drug | increases expression | EXP | | 6480464 | Antirheumatic Agents results in increased expression of NR2F1-AS1 mRNA | CTD | PMID:24449571 | NR2F1-AS1 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of NR2F1-AS1 promoter | CTD | PMID:27901495 | NR2F1-AS1 | Human | benzo[e]pyrene | increases methylation | EXP | | 6480464 | benzo(e)pyrene results in increased methylation of NR2F1-AS1 intron | CTD | PMID:30157460 | NR2F1-AS1 | Human | butanal | decreases expression | EXP | | 6480464 | butyraldehyde results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:26079696 | NR2F1-AS1 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:27392435 | NR2F1-AS1 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:27392435 | NR2F1-AS1 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | NR2F1-AS1 | Human | entinostat | decreases expression | EXP | | 6480464 | entinostat results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:26272509 | NR2F1-AS1 | Human | entinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:27188386 | NR2F1-AS1 | Human | mercury dibromide | decreases expression | EXP | | 6480464 | mercuric bromide results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:26272509 | NR2F1-AS1 | Human | mercury dibromide | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:27188386 | NR2F1-AS1 | Human | methapyrilene | increases methylation | EXP | | 6480464 | Methapyrilene results in increased methylation of NR2F1-AS1 intron | CTD | PMID:30157460 | NR2F1-AS1 | Human | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:28001369 | NR2F1-AS1 | Human | p-chloromercuribenzoic acid | decreases expression | EXP | | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:26272509 | NR2F1-AS1 | Human | p-chloromercuribenzoic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:27188386 | NR2F1-AS1 | Human | pentanal | decreases expression | EXP | | 6480464 | pentanal results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:26079696 | NR2F1-AS1 | Human | propofol | increases expression | EXP | | 6480464 | Propofol results in increased expression of NR2F1-AS1 mRNA | CTD | PMID:35238236 | NR2F1-AS1 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | NR2F1-AS1 | Human | silicon dioxide | decreases expression | EXP | | 6480464 | Silicon Dioxide analog results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:25895662 | NR2F1-AS1 | Human | trichostatin A | decreases expression | EXP | | 6480464 | trichostatin A results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:26272509 | NR2F1-AS1 | Human | trichostatin A | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:27188386 | NR2F1-AS1 | Human | valproic acid | increases methylation | EXP | | 6480464 | Valproic Acid results in increased methylation of NR2F1-AS1 gene | CTD | PMID:29154799 | NR2F1-AS1 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:26272509 | NR2F1-AS1 | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA | CTD | PMID:27188386 | NR2F1-AS1 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of NR2F1-AS1 mRNA | CTD | PMID:28001369 | |